AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026050058
Submit to EJMO
Cite this article
4
Download
25
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW ARTICLE

Progress in the surgical treatment of early-stage malignant melanoma

Jingqun Zhang1 ,  Zhenpeng Zhu2* ,  Wenliang Han1*
Show Less
1 Department of Burn and Plastic Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
2 Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
EJMO, 026050058 https://doi.org/10.36922/EJMO026050058
Received: 31 January 2026 | Revised: 2 March 2026 | Accepted: 9 March 2026 | Published online: 27 April 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Surgical treatment of early-stage malignant melanoma has shifted from traditional wide margins to precise, individualized approaches. This article systematically reviews the standards for surgical margin width and their impact on locoregional recurrence and survival outcomes, emphasizing how tumor thickness and anatomical location guide margin design. Sentinel lymph node biopsy, an important staging and prognostic tool, has greatly improved detection accuracy and safety through technological innovation and multimodal imaging, gradually replacing traditional lymphadenectomy and supporting more evidence-based treatment decisions. Mohs micrographic surgery, a minimally invasive, precise-margin technique, has shown significant advantages in functionally sensitive areas and specific tumor subtypes, achieving real-time comprehensive pathological assessment of margins and maximizing functional preservation, thereby reducing locoregional recurrence rates. Advances in systemic therapies, particularly immunotherapy and targeted therapy, are profoundly reshaping the timing and scope of surgeries through models such as neoadjuvant therapy, promoting a “response–adaptive” surgical approach. Individualized surgical strategies based on patient age, tumor thickness, molecular characteristics, and tumor location differences allow rational adjustment of surgical margins and adjuvant treatment planning, while integration with neoadjuvant and adjuvant systemic therapies may reduce operative extent, postoperative complications, and impairment in quality of life. Multidisciplinary cooperation and the integration of telemedicine technology also play key roles in surgical decision-making and follow-up. Looking ahead, the surgical treatment of early-stage malignant melanoma will further integrate molecular biology and advanced imaging technologies for precise staging and precise surgery, transform unresectable lesions through neoadjuvant therapy, and establish new models of minimally invasive and individualized treatment, ultimately improving patient survival rates and quality of life.

Keywords
Early-stage melanoma
Surgical margins
Sentinel lymph node biopsy
Lymphadenectomy
Mohs micrographic surgery
Neoadjuvant therapy
Funding
None.
Conflict of interest
The authors declare no conflicts of interest related to this study.
References
  1. Felcht M, Fischer JC, Michels M, Weinhold M, Zouboulis CC. Malignes Melanom -- Eine Betrachtung von Studenten der Humanmedizin [Malignant melanoma—a medical students’ viewpoint]. J Dtsch Dermatol Ges. 2005;3(6):421- 430. [In German]. doi: 10.1111/j.1610-0387.2005.05024.x
  2. Koizumi S, Inozume T, Nakamura Y. Current surgical management for melanoma. J Dermatol. 2023;51(3):312- 323. doi: 10.1111/1346-8138.17086
  3. Desai VM, Dutta S, Saoji K, et al. Harnessing cold atmospheric plasma for skin cancer: a non-invasive breakthrough in plasma medicine. Drug Discov Today. 2025;30(11):104491. doi: 10.1016/j.drudis.2025.104491
  4. Liu Y, Yang D, Fu X, et al. Surgery vs non-surgery in cutaneous melanoma based on SEER database. Medicine. 2021;100(12):e25120. doi: 10.1097/md.0000000000025120
  5. Chandra SR, Singu S, Foster J. Principles of Surgery in Head and Neck Cutaneous Melanoma. Oral Maxillofac Surg Clin North Am. 2022;34(2):251-262. doi: 10.1016/j.coms.2021.11.006
  6. Falk Delgado A, Zommorodi S, Falk Delgado A. Sentinel Lymph Node Biopsy and Complete Lymph Node Dissection for Melanoma. Curr Oncol Rep. 2019;21(6):54. doi: 10.1007/s11912-019-0798-y
  7. Rosenthal A, Juhasz M, Lask G, Gharavi N. From Centimeters to Millimeters: The Evolution of the Surgical Margins for Melanoma-A Historical Review. Dermatol Surg. 2023;49(12):1058-1060. doi: 10.1097/dss.0000000000003926
  8. Lee C, Collichio F, Ollila D, Moschos S. Historical review of melanoma treatment and outcomes. Clin Dermatol. 2013;31(2):141-147. doi: 10.1016/j.clindermatol.2012.08.015
  9. Argenziano G, Fabbrocini G, Carli P, De Giorgi V, Delfino M. Clinical and dermatoscopic criteria for the preoperative evaluation of cutaneous melanoma thickness. J Am Acad Dermatol. 1999;40(1):61-68. doi: 10.1016/s0190-9622(99)70528-1
  10. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am. 2003;83(1):109-156. doi: 10.1016/s0039-6109(02)00205-0
  11. Kádár Z, Lengyel Z, Gyulai R. A melanoma malignum sebészeti ellátása – Elvárható standardok [Surgical treatment of malignant melanoma – Expected standards]. Magy Seb. 2023;76(1):39-47. [In Hungarian]. doi: 10.1556/1046.2023.10007
  12. Wright FC, Souter LH, Kellett S, et al. Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline. Curr Oncol. 2019;26(4):e541-e550. doi: 10.3747/co.26.4885
  13. Morton DL, Cochran AJ, Thompson JF. Authors’ response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg. 2007;245(5):828-829. doi: 10.1097/01.sla.0000261157.79250.16
  14. Alter M, Gutzmer R. Stellenwert der Chirurgie des malignen Melanoms im Kontext aktueller adjuvanter und neoadjuvanter Therapiekonzepte [The importance of surgery for malignant melanoma in the context of current adjuvant and neoadjuvant therapy concepts]. Die Dermatologie. 2025;76(6):365-370. [In German]. doi: 10.1007/s00105-025-05511-2
  15. McCahill LE. Changes in the surgical management of melanoma and measures to implement change. Am J Surg. 2025;241:116129. doi: 10.1016/j.amjsurg.2024.116129
  16. Jacobsen ES, Soleymani T. Mohs Micrographic Surgery for the Treatment of Cutaneous Melanomas of the Head and Neck. Oral Maxillofac Surg Clin North Am. 2022;34(2):263- 271. doi: 10.1016/j.coms.2021.11.005
  17. Kokkinos C, Sorkin T, Powell B. To Mohs or not to Mohs. J Plast Reconstr Aesthet Surg. 2014;67(1):23-26. doi: 10.1016/j.bjps.2013.08.022
  18. Campbell EH, Crum OM, Chelf CJ, Demer AM, Brewer JD. Local Recurrence Rates of Malignant Melanoma After Mohs Micrographic Surgery Are Lowest With 5- to 10-mm Initial Margins: A Systematic Review and Meta-Analysis. Dermatol Surg. 2023;49(2):119-123. doi: 10.1097/dss.0000000000003683
  19. Charalambides M, Yannoulias V, Malik N, et al. A review of Mohs micrographic surgery for skin cancer. Part 1: Melanoma and rare skin cancers. Clin Exp Dermatol. 2022;47(5):833-849. doi: 10.1111/ced.15081
  20. Asamoah EM, Demer AM, Trischman TE, Bangalore Kumar A, Vidal NY, Wagner LH. Immunohistochemistry-Assisted Mohs Surgery for Invasive Eyelid and Periorbital Cutaneous Melanoma. Dermatol Surg. 2025;51(2):127-133. doi: 10.1097/dss.0000000000004423
  21. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998;5(4):322- 328. doi: 10.1007/bf02303495
  22. Hauschild A, Rosien F, Lischner S. Surgical standards in the primary care of melanoma patients. Onkologie. 2003;26(3):218-222. doi: 10.1159/000071616
  23. Phan K, Loya A. Mohs micrographic surgery versus wide local excision for melanoma in situ: analysis of a nationwide database. Int J Dermatol. 2019;58(6):697-702. doi: 10.1111/ijd.14374
  24. Thacoor A, Odili J. A perioperative protocol for the management of patent blue V dye-induced hypersensitivity reaction during sentinel lymph node biopsy for cutaneous melanoma. J Plast Reconstr Aesthet Surg. 2023;79:55-57. doi: 10.1016/j.bjps.2023.01.023
  25. Müller CSL, Hauer N, Kofler K, Kofler L. Mikroskopisch kontrollierte Chirurgie im dermatochirurgischen Alltag [Micrographic controlled surgery in everyday dermatosurgery]. Dermatologie (Heidelb). 2023;74(6):457- 470. [In German]. doi: 10.1007/s00105-023-05158-x
  26. Huerta T, Swetter SM, Nehal KS, Coit DG, Bichakjian CK, Durham AB. Current evidence does not support Mohs micrographic surgery or staged excision as equivalent to wide excision for primary cutaneous melanoma. J Am Acad Dermatol. 2023;88(4):959-960. doi: 10.1016/j.jaad.2022.12.018
  27. Bund V, Lecointre L, Akladios C. The saga of lymph node surgery in malignant melanoma: a history repeating itself in gynecologic oncology. Chin Clin Oncol. 2021;10(2):21. doi: 10.21037/cco-20-227
  28. Kofler L, Ziemer M, Andrulis M, et al. S1-Guideline: Microscopically controlled surgery. J Dtsch Dermatol Ges. 2022;20(12):1663-1674. doi: 10.1111/ddg.14910
  29. Kato H, Kano S, Yoshimitsu M, et al. Comparative analysis of one-step and two-step full thickness skin grafting and secondary intention healing for skin defects after surgical management of plantar malignant melanoma. J Dermatol. 2024;51(12):1641-1645. doi: 10.1111/1346-8138.17398
  30. Fortes C, Mastroeni S, Caggiati A, et al. The effect of time to sentinel lymph node biopsy on cutaneous melanoma survival. Am J Surg. 2016;212(5):935-940. doi: 10.1016/j.amjsurg.2016.02.025
  31. Rathod D, Kroumpouzos G, Lallas A, et al. Critical Review of the Sentinel Lymph Node Surgery in Malignant Melanoma. J Drugs Dermatol. 2022;21(5):510-516. doi: 10.36849/jdd.6198
  32. Klode J, Dissemond J, Grabbe S, Hillen U, Poeppel T, Boeing C. Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II. Dermatol Surg. 2010;36(4):439-445. doi: 10.1111/j.1524-4725.2010.01479.x
  33. Borgognoni L, Crocetti E, Sestini S, Brandani P, Giannotti V, Gerlini G. The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy. Melanoma Res. 2022;32(6):469-476. doi: 10.1097/cmr.0000000000000851
  34. Holmberg CJ, Mikiver R, Isaksson K, et al. Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm). Ann Surg Oncol. 2023;30(13):8026- 8033. doi: 10.1245/s10434-023-14050-w
  35. Shannon AB, Sharon CE, Straker RJ, et al. Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study. J Am Acad Dermatol. 2023;88(1):52-59. doi: 10.1016/j.jaad.2022.09.040
  36. Kretschmer L, Hilgers R, Möhrle M, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004;40(2):212-218. doi: 10.1016/j.ejca.2003.07.003
  37. Gambichler T, Bünnemann H, Scheel CH, et al. Does very early timing of lymph node surgery after resection of the primary tumour improve the clinical outcome of patients with melanoma? Clin Exp Dermatol. 2020;45(8):1011-1018. doi: 10.1111/ced.14291
  38. Ulrich J, van Akkooi AJ, Eggermont AM, Voit C. New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB). Expert Rev Anticancer Ther. 2011;11(11):1693-1701. doi: 10.1586/era.11.115
  39. Deng XH, Du ZS, Wu ZG, Chen Y, Wu XY, Tang LN. The Value of Contrast-Enhanced Ultrasound in the Detection of Sentinel Lymph Nodes in Malignant Melanoma. J Ultrasound Med. 2023;42(5):1015-1022. doi: 10.1002/jum.16110
  40. Beger J, Hansel G, Krönert C, Fuchs M, et al. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013;52(2):220-230. doi: 10.1111/j.1365-4632.2012.05706.x
  41. Wong ZY, Damavandi P, Misky AT, et al. Timing of sentinel lymph node biopsy and lymphoscintigraphy before surgery for melanoma: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2025;101:196-204. doi: 10.1016/j.bjps.2024.11.062
  42. Wollina U, Langner D, Schönlebe J, et al. Sentinel- Lymphonodektomie bei frühem Melanom – Vergleich zweier Techniken zur Sentinel-Entnahme [Sentinel lymph node biopsy in early melanoma-comparison of two techniques for sentinel removal]. Wien Med Wochenschr. 2017;167(5-6):100-103. [In German]. doi: 10.1007/s10354-016-0499-1
  43. Watt MM, Moitra P, Sheffield Z, Ostadhossein F, Maxwell EA, Pan D. A narrative review on the role of carbon nanoparticles in oncology. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15(2):e1845. doi: 10.1002/wnan.1845
  44. Luo J, Feng L, Zhou Q, et al. The value of contrast-enhanced ultrasound in determining the location of sentinel lymph nodes in breast cancer. Cancer Imaging. 2021;21(1):28. doi: 10.1186/s40644-021-00397-4
  45. Mills O, Messina JL. Pediatric melanoma: a review. Cancer Control. 2009;16(3):225-233. doi: 10.1177/107327480901600304
  46. Sayan A, Plant R, Eccles B, Davies C, Ilankovan V. Recent advances in the management of cutaneous malignant melanoma: our case cohort. Br J Oral Maxillofac Surg. 2021;59(5):534-545. doi: 10.1016/j.bjoms.2020.11.008
  47. Williams TS, Tallon B, Adams BM. Melanoma sentinel lymph node biopsy and completion lymph node dissection: A regional hospital experience. J Plast Reconstr Aesthet Surg. 2022;75(2):730-736. doi: 10.1016/j.bjps.2021.09.077
  48. Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol. 2014;170(1):20-30. doi: 10.1111/bjd.12687
  49. Helgadottir H, Ny L, Ullenhag GJ, Mikiver R, Isaksson K, Olofsson Bagge R. Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. Eur J Cancer. 2026;234:116201. doi: 10.1016/j.ejca.2025.116201
  50. Cohen DK, Goldberg DJ. Mohs Micrographic Surgery: Past, Present, and Future. Dermatol Surg. 2019;45(3):329-339. doi: 10.1097/dss.0000000000001701
  51. Cammarata E, Esposto E, Veronese F, et al. Safety margins for dermatofibrosarcoma protuberans: a comparison between wide local excision and Mohs Tubingen technique. Eur J Dermatol. 2020;30(3):289-293. doi: 10.1684/ejd.2020.3771
  52. Burshtein J, Marson J, Shah M, et al. Mohs Micrographic Surgery for Melanoma. Dermatol Clin. 2025;43(3):473-482. doi: 10.1016/j.det.2025.03.003
  53. Cánovas Seva C, Martínez Leboráns L, Batalla A, Sánchez- Aguilar YRMD, Flórez Á. Lentigo Maligna: Contemporary Surgical Management and Outcome: A Review. Ann Ital Chir. 2026;97(1):36-62. doi: 10.62713/aic.4228
  54. Brodland DG. Mohs Micrographic Surgery for Melanoma: Evidence, Controversy, and a Critical Review of Excisional Margin Guidelines. Dermatol Clin. 2023;41(1):79-88. doi: 10.1016/j.det.2022.07.008
  55. Young JN, Nguyen TA, Freeman SC, et al. Permanent section margin concordance after Mohs micrographic surgery with immunohistochemistry for invasive melanoma and melanoma in situ: A retrospective dual-center analysis. J Am Acad Dermatol. 2023;88(5):1060-1065. doi: 10.1016/j.jaad.2023.01.019
  56. Cheraghlou S, Christensen SR, Leffell DJ, Girardi M. Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a- T2a Invasive Melanoma. JAMA Dermatol. 2021;157(5):531- 539. doi: 10.1001/jamadermatol.2021.0023
  57. Blessley-Redgrave N, Bowerman F, Dafydd H, Hemington- Gorse S, Boyce D. Malignant melanoma in the hand: current evidence and recommendations. J Hand Surg Eur Vol. 2024;49(7):831-842. doi: 10.1177/17531934241245028
  58. Zitelli JA, Stiegel E, Brodland DG. The Controversy and Value of Mohs Micrographic Surgery for Melanoma and Melanoma in Situ on the Trunk and Extremities. Dermatol Surg. 2023;49(12):1061-1065. doi: 10.1097/dss.0000000000004002
  59. Demer AM, Hanson JL, Maher IA, Liszewski W. Association of Mohs Micrographic Surgery vs Wide Local Excision With Overall Survival Outcomes for Patients With Melanoma of the Trunk and Extremities. JAMA Dermatol. 2021;157(1):84- 89. doi: 10.1001/jamadermatol.2020.3950
  60. Christodoulides N, Quirke N, Leon R, Ghinis A, Jeantet Q, Potter S. Validation and clinical utility of predictive nomograms for sentinel node positivity in cutaneous malignant melanoma in Ireland. Surgeon. 2026. doi: 10.1016/j.surge.2026.02.003
  61. Ma EZ, Terhune JH, Zafari Z, et al. Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma. J Am Coll Surg. 2022;234(4):521-528. doi: 10.1097/xcs.0000000000000088
  62. Buzaid AC, Anderson CM. The changing prognosis of melanoma. Curr Oncol Rep. 2000;2(4):322-328. doi: 10.1007/s11912-000-0025-9
  63. Razzaq A, Shahad M, Ditta AA. Clinicopathological Factors Predicting Melanoma Recurrence: A Study From South East Ireland. Dermatol Pract Concept. 2025;15(4):6006. doi: 10.5826/dpc.1504a6006
  64. Zhang Y, Foth I, Makky A, et al. Modeling immunotherapies in live 3D human cancer tissue bioreactors. Theranostics. 2026;16(8):3928-3945. doi: 10.7150/thno.118298
  65. Lytchiér JVC, Okur MI, Rutkowski W, Helgadottir H, Falk Delgado A. Surgical complications after therapeutic lymph node dissection in stage III-IV melanoma: impact of neoadjuvant immunotherapy. Eur J Surg Oncol. 2026;52(3):111403. doi: 10.1016/j.ejso.2026.111403
  66. Jeremić J, Radenović K, Jurišić M, et al. Primary Melanoma Histopathologic Predictors of Sentinel Lymph Node Positivity: A Proposed Scoring System for Risk Assessment and Patient Selection in a Clinical Setting. Medicina (Kaunas). 2023;59(11):1921. doi: 10.3390/medicina59111921
  67. Szumera-Ciećkiewicz A, Donizy P, Kervarrec T, et al. An updated European organization for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for merkel cell carcinoma (MCC). Eur J Cancer. 2026;237:116587. doi: 10.1016/j.ejca.2026.116587
  68. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. Eur J Cancer. 2025;215:115153. doi: 10.1016/j.ejca.2024.115153
  69. Passman JE, Kallan MJ, Roberson JL, et al. Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies. Cancer. 2025;131(1):e35664. doi: 10.1002/cncr.35664
  70. Na H, Oakley A. Timeliness of diagnosis and treatment of cutaneous melanoma with dermatology, general practice, plastics surgery collaboration - are we meeting standards? J Prim Health Care. 2023;15(3):267-273. doi: 10.1071/hc23013

71. Naeser Y, Helgadottir H, Brandberg Y, et al. TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma. BMC Cancer. 2020;20(1):1197. doi: 10.1186/s12885-020-07632-4

Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept